Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%

MT Newswires Live

09/15

Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with Kexing Biopharm (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.

Shares of the firm were up nearly 7% in Monday morning trade.

The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.

Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.

The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2567194040"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567194040\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567194040?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-15 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567194040","market":"sg","top_or_hot":-1,"title":"Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%","media":"MT Newswires Live","content":"<html><body><p> Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with <a href=\"https://laohu8.com/S/688136\">Kexing Biopharm</a> (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.</p><p>Shares of the firm were up nearly 7% in Monday morning trade.</p><p>The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.</p><p>Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.</p><p>The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-09-15 10:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with <a href=\"https://laohu8.com/S/688136\">Kexing Biopharm</a> (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.</p><p>Shares of the firm were up nearly 7% in Monday morning trade.</p><p>The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.</p><p>Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.</p><p>The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2567194040","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567194040","pubTimestamp":1757904230,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Uni-Bio Science Group  said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with Kexing Biopharm  to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.Shares of the firm were up nearly 7% in Monday morning trade.The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688136":"科兴制药","BK1161":"生物科技","00690":"联康生物科技集团","BK0239":"医药制造"},"translate_title":"Uni-Bio Science与科兴生物制药合作，将博古泰在六个市场商业化；股价上涨7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688136":0.9,"00690":0.9},"content_text":"Uni-Bio Science Group (HKG:0690) said its unit, Beijing Genetech Pharmaceutical, has entered into a strategic cooperation agreement with Kexing Biopharm (SHA:688136) to commercialize its osteoporosis treatment Bogutai, according to a Friday Hong Kong bourse filing.Shares of the firm were up nearly 7% in Monday morning trade.The agreement grants Kexing Biopharm exclusive rights to market Bogutai in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico.Bogutai, a pre-filled pen-type teriparatide injection launched in China in March 2024, is used for postmenopausal women at high risk of fractures.The partnership will target markets with more than 10 million osteoporosis patients and an estimated value of nearly $1.5 billion, with revenue expected from late 2026.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}